Cell Source Stock Today
| CLCS Stock | USD 0.56 0.05 8.20% |
Performance7 of 100
| Odds Of DistressLess than 10
|
Cell Source is selling for under 0.56 as of the 22nd of November 2024; that is 8.2 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.4. Cell Source has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Cell Source are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 35.25 M outstanding shares. More on Cell Source
Moving against Cell OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cell OTC Stock Highlights
| CEO | Itamar Shimrat |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Cell Source [CLCS] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cell Source's market, we take the total number of its shares issued and multiply it by Cell Source's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cell Source conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 35.25 M outstanding shares.
Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations.
Check Cell Source Probability Of Bankruptcy
Ownership AllocationCell Source holds a total of 35.25 Million outstanding shares. Cell Source retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cell Ownership Details
Cell Source Risk Profiles
| Mean Deviation | 9.4 | |||
| Semi Deviation | 10.13 | |||
| Standard Deviation | 16.29 | |||
| Variance | 265.31 |
Cell Stock Against Markets
Picking the right benchmark for Cell Source otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cell Source otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cell Source is critical whether you are bullish or bearish towards Cell Source at a given time. Please also check how Cell Source's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cell Source without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.